Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> reported strong financial performance for the first three quarters of FY26, with revenue and operating profit reporting double-digit growth and net profit recording triple-digit growth.</li>
<li>Revenue from medical division increased 15% YoY to ¥95B, driven by broad-based growth covering all geographical regions and treatment fields. Key markets including U.S., Europe, and China reported double-digit growth.</li>
<li>With 9MFY26 revenue, operating profit, and net profit recording progress rate of 77%, 89%, and 87% against full-year forecast, the company is well-positioned to meet FY guidance.</li>
</ul>



Asahi Intecc (7747 JP) reported strong financial performance for the first three quarters of FY26, with revenue and operating profit reporting double-digit growth and net profit recording triple-digit growth.
Revenue from medical division increased 15% YoY to ¥95B, driven by broad-based growth covering all geographical regions and treatment fields. Key markets including U.S., Europe, and China reported double-digit growth.
With 9MFY26 revenue, operating profit, and net profit recording progress rate of 77%, 89%, and 87% against full-year forecast, the company is well-positioned to meet FY guidance.


Asahi Intecc (7747 JP): Well-Positioned to Meet FY Guidance; Long-Term Growth Levers Intact

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> has reported strong financial results for H1FY26, with accelerated double-digit growth in key parameters including revenue, operating profit, and net profit.</li>
<li>Revenue from medical division increased 12% YoY to ¥63B. Asahi’s mainstay cardiovascular business performed well in all the regions, with PCI guidewire and penetration catheter seeing strong demand.</li>
<li>Amid expanding demand and better-than-expected foreign exchange rates, Asahi Intecc has revised FY26 guidance upward. The company expects FY26 revenue growth of 18% and operating profit growth of 40%.</li>
</ul>



Asahi Intecc (7747 JP) has reported strong financial results for H1FY26, with accelerated double-digit growth in key parameters including revenue, operating profit, and net profit.
Revenue from medical division increased 12% YoY to ¥63B. Asahi’s mainstay cardiovascular business performed well in all the regions, with PCI guidewire and penetration catheter seeing strong demand.
Amid expanding demand and better-than-expected foreign exchange rates, Asahi Intecc has revised FY26 guidance upward. The company expects FY26 revenue growth of 18% and operating profit growth of 40%.


Asahi Intecc (7747 JP): Strong Demand Drives H1FY26 Performance and FY26 Guidance Raise

Thematic (Sector/Industry)

<ul>
<li>Hengrui Pharmaceuticals’ trastuzumab rezetecan got third indication approval in China for colorectal cancer. CSPC Pharma and AstraZeneca entered JV contract for the construction of new-generation biologics manufacturing facility in China.</li>
<li>Takeda Pharmaceutical got FDA approval for Orzeyful for narcolepsy type 1. As a first-in-class orexin treatment, Orzeyful is the only medicine indicated in the U.S. to treat the disease holistically.</li>
<li>Otsuka announced new data from the Phase 3 trial demonstrating that Voyxact stabilizes kidney function decline. Alteogen signed an exclusive license agreement with a global pharmaceutical company for ALT-B4. </li>
</ul>


Hengrui Pharmaceuticals’ trastuzumab rezetecan got third indication approval in China for colorectal cancer. CSPC Pharma and AstraZeneca entered JV contract for the construction of new-generation biologics manufacturing facility in China.
Takeda Pharmaceutical got FDA approval for Orzeyful for narcolepsy type 1. As a first-in-class orexin treatment, Orzeyful is the only medicine indicated in the U.S. to treat the disease holistically.
Otsuka announced new data from the Phase 3 trial demonstrating that Voyxact stabilizes kidney function decline. Alteogen signed an exclusive license agreement with a global pharmaceutical company for ALT-B4. 


APAC Healthcare Weekly (August 9) – Hengrui, CSPC Pharma, Takeda Pharma, Otsuka, Alteogen

<ul>
<li>Wuxi XDC partnered with Akari Therapeutics to accelerate IND filing for Akari’s ADC program. Xuanzhu Biopharmaceutical entered licensing agreement with Boston Oncology for upfront and milestone payments of $100M+.</li>
<li>Shionogi secured $119M BARDA contract for manufacturing, procurement, and expanded development of Fetroja for biothreat-related infections. ABL Bio’s partner has received Orphan Drug Designation from the FDA for tovecimig.</li>
<li>PharmaEssentia signed an investment agreement for a new manufacturing facility in Puerto Rico. Max Healthcare Institute is acquiring 58.4% stake in 250-bedded Kalinga Hospital for INR3B.</li>
</ul>


Wuxi XDC partnered with Akari Therapeutics to accelerate IND filing for Akari’s ADC program. Xuanzhu Biopharmaceutical entered licensing agreement with Boston Oncology for upfront and milestone payments of $100M+.
Shionogi secured $119M BARDA contract for manufacturing, procurement, and expanded development of Fetroja for biothreat-related infections. ABL Bio’s partner has received Orphan Drug Designation from the FDA for tovecimig.
PharmaEssentia signed an investment agreement for a new manufacturing facility in Puerto Rico. Max Healthcare Institute is acquiring 58.4% stake in 250-bedded Kalinga Hospital for INR3B.


APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia

Japan Specialist

Mark Chadwick

<ul>
<li>Japanese equities traded broadly flat this week, with performance shaped by sector rotation rather than index direction.</li>
<li>Investors rotated decisively into “hardware” and national security–linked sectors, reflecting policy signals from Prime Minister Sanae Takaichi</li>
<li>GS Yuasa was the top performer this week, after the company announced plans to build a new lithium-ion battery plant for energy storage systems</li>
</ul>


Japanese equities traded broadly flat this week, with performance shaped by sector rotation rather than index direction.
Investors rotated decisively into “hardware” and national security–linked sectors, reflecting policy signals from Prime Minister Sanae Takaichi
GS Yuasa was the top performer this week, after the company announced plans to build a new lithium-ion battery plant for energy storage systems


Japan Strategy Weekly | From Austerity to Strategic Investment

Japan

ASAHI INTECC CO., LTD. manufactures medical tools as well as both medical and industrial-use stainless wire rope.  The Company's main products include catheters, guidewires, and miniature coils for endoscopic devices.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Asahi Intecc (7747 JP)